Question 1

What is Alnylam Pharmaceuticals's P/B ratio?

Accepted Answer

Alnylam Pharmaceuticals (ALNY) P/B ratio is 39.0× as of June 5, 2026. The ratio is calculated by dividing market capitalisation by book value of equity, using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/B ratio calculated?

Accepted Answer

P/B = Market Capitalisation ÷ Book Value of Equity (most recent quarterly shareholders' equity), or equivalently Share Price ÷ Book Value Per Share. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/B ratio?

Accepted Answer

The price-to-book (P/B) ratio compares a company's market capitalisation to its book value of equity (total shareholders' equity) on the most recent quarterly balance sheet. It is calculated as market cap ÷ book value of equity (equivalent to share price ÷ book value per share). A P/B below 1× implies the market values the business below its accounting net worth; values well above 1× reflect intangible assets, brand value, or a high return on equity.

Question 4

What is a good P/B ratio for Alnylam Pharmaceuticals?

Accepted Answer

A "good" P/B depends on the business model. Banks, insurers, and other capital-heavy financials typically trade near 1×; asset-light technology and consumer-brand companies can sustainably trade at 5×+ because much of their value is intangible. P/B is most informative when paired with return on equity (ROE). For Alnylam Pharmaceuticals specifically, the relevant sector benchmark is the current sector median of 3.4×.

Question 5

Is Alnylam Pharmaceuticals's P/B ratio high or low?

Accepted Answer

Alnylam Pharmaceuticals's P/B ratio of 39.0× is below its own 5-year average of 218.1× and above the sector median of 3.4×. That places the current reading at the 35th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is Alnylam Pharmaceuticals's historical P/B ratio range?

Accepted Answer

In the available daily series, Alnylam Pharmaceuticals (ALNY) P/B ratio has ranged from a low of 1.0× in 2004 to a high of 1112.1× in 2024. The 5-year average is 218.1× and the 5-year median is 83.4×.

Question 7

What was Alnylam Pharmaceuticals's P/B ratio in 2025?

Accepted Answer

Alnylam Pharmaceuticals (ALNY) P/B ratio at the end of 2025 was 66.6×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month book value figure available at that date.

Question 8

Why does Alnylam Pharmaceuticals's P/B ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (book value). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$52.58B	$789.18M	66.6×	-384.4×	Dec 31, 2025
2024	$30.26B	$67.09M	451.0×	—	Dec 31, 2024
2023	$24.04B	−$220.64M	—	—	Dec 31, 2023
2022	$29.29B	−$158.22M	—	—	Dec 31, 2022
2021	$20.31B	$588.20M	34.5×	+19.7×	Dec 31, 2021
2020	$15.11B	$1.02B	14.9×	+5.9×	Dec 31, 2020
2019	$12.87B	$1.44B	8.9×	+3.3×	Dec 31, 2019
2018	$7.37B	$1.30B	5.7×	-1.3×	Dec 31, 2018
2017	$12.21B	$1.77B	6.9×	+3.4×	Dec 31, 2017
2016	$3.21B	$920.22M	3.5×	-2.8×	Dec 31, 2016
2015	$7.99B	$1.26B	6.3×	-1.7×	Dec 31, 2015
2014	$7.46B	$936.27M	8.0×	-7.0×	Dec 31, 2014
2013	$4.05B	$270.35M	15.0×	+7.9×	Dec 31, 2013
2012	$945.73M	$134.05M	7.1×	+3.9×	Dec 31, 2012
2011	$376.61M	$118.00M	3.2×	+0.6×	Dec 31, 2011
2010	$416.02M	$158.23M	2.6×	-1.5×	Dec 31, 2010
2009	$737.75M	$177.97M	4.1×	-0.9×	Dec 31, 2009
2008	$1.02B	$202.13M	5.1×	-0.9×	Dec 31, 2008
2007	$1.18B	$199.17M	5.9×	+2.0×	Dec 31, 2007
2006	$799.85M	$201.17M	4.0×	-2.5×	Dec 31, 2006
2005	$401.17M	$61.78M	6.5×	+3.2×	Dec 31, 2005
2004	$152.65M	$46.14M	3.3×	—	Dec 31, 2004
2003	$9.95M	−$26.71M	—	—	Dec 31, 2003


Quest Diagnostics (DGX)	2.9×
Moderna (MRNA)	2.7×
Charles River (CRL)	2.6×
Regeneron Pharmaceuticals (REGN)	2.6×
Henry Schein (HSIC)	2.5×
Labcorp Holdings (LH)	2.5×
Danaher (DHR)	2.4×
UnitedHealth Group (UNH)	2.4×
Solventum (SOLV)	2.3×
Becton, Dickinson and (BDX)	1.8×
Pfizer (PFE)	1.8×
Molina Healthcare (MOH)	1.7×
Cigna (CI)	1.7×
Waters Corporation (WAT)	1.6×
Cooper Companies (COO)	1.5×
Elevance Health (ELV)	1.5×
Universal Health Services (UHS)	1.5×
Biogen (BIIB)	1.4×
Baxter International (BAX)	1.4×
Revvity (RVTY)	1.4×
Zimmer Biomet Holdings (ZBH)	1.2×
CVS Health (CVS)	1.2×
Humana (HUM)	1.1×
Viatris (VTRS)	1.1×
Centene (CNC)	0.8×

P/B Ratio for Alnylam Pharmaceuticals (ALNY)

P/B Ratio daily chart for Alnylam Pharmaceuticals (ALNY)

Historical P/B Ratio for Alnylam Pharmaceuticals (ALNY) from 2003 to 2025

About P/B Ratio at Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals P/B Ratio by Year

Alnylam Pharmaceuticals P/B Ratio 2025: 66.6×

Alnylam Pharmaceuticals P/B Ratio 2024: 451.0×

Alnylam Pharmaceuticals P/B Ratio 2021: 34.5×

Alnylam Pharmaceuticals P/B Ratio 2020: 14.9×

Alnylam Pharmaceuticals P/B Ratio 2019: 8.9×

Sector peers by P/B Ratio — chart

Sector peers by P/B Ratio — table

Frequently asked questions

Alnylam Pharmaceuticals (ALNY) Key Financials

P/B Ratio daily chart for Alnylam Pharmaceuticals (ALNY)

Historical P/B Ratio for Alnylam Pharmaceuticals (ALNY) from 2003 to 2025

About P/B Ratio at Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals P/B Ratio by Year

Alnylam Pharmaceuticals P/B Ratio 2025: 66.6×

Alnylam Pharmaceuticals P/B Ratio 2024: 451.0×

Alnylam Pharmaceuticals P/B Ratio 2021: 34.5×

Alnylam Pharmaceuticals P/B Ratio 2020: 14.9×

Alnylam Pharmaceuticals P/B Ratio 2019: 8.9×

Sector peers by P/B Ratio — chart

Sector peers by P/B Ratio — table

Frequently asked questions

+What is Alnylam Pharmaceuticals's P/B ratio?

+How is the P/B ratio calculated?

+What is the P/B ratio?

+What is a good P/B ratio for Alnylam Pharmaceuticals?

+Is Alnylam Pharmaceuticals's P/B ratio high or low?

+What is Alnylam Pharmaceuticals's historical P/B ratio range?

+What was Alnylam Pharmaceuticals's P/B ratio in 2025?

+Why does Alnylam Pharmaceuticals's P/B ratio change over time?

Alnylam Pharmaceuticals (ALNY) Key Financials